share_log

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying

anixa biosciences和其他3只股票的內部人士正在購買
Benzinga ·  07/29 07:13

The Dow Jones index closed higher by over 650 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週五收盤上漲了650多點。當內部人士購買或出售股票時,這表明他們對公司前景的信心或擔憂。對於對便士股感興趣的投資者和交易者,他們可以將此視爲其整體投資或交易決策的因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是幾個近期關於低價股的值得關注的內部交易。了解更多,請查看Benzinga內幕交易平台。

ARCA biopharma

方舟生物醫藥

  • The Trade: ARCA biopharma, Inc. (NASDAQ:ABIO) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd bought a total of 220,083 shares at an average price of $3.18. To acquire these shares, it cost around $699,165.
  • What's Happening: On April 25, ARCA biopharma posted a first-quarter loss of 14 cents per share.
  • What ARCA biopharma Does: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases.
  • 交易:ARCA生物製藥公司(納斯達克:ABIO)的10%股東珍珠昆士蘭生物醫學創新主基金有限公司以平均價格3.18美元購買了220083股。爲了獲得這些股票,花費約爲699165美元。
  • 動態:4月25日,方舟生物醫藥公佈第一季度每股虧損14美分。
  • 方舟生物醫藥公司是一家臨床階段的生物醫藥公司,採用精準醫學方法開發和商業化心血管疾病的靶向治療方案。

Anixa Biosciences

Anixa生物科技

  • The Trade: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M Baskies acquired a total of 5,000 shares at an average price of $3.09. To acquire these shares, it cost around $15,450.
  • What's Happening: On July 23, Anixa Biosciences announced that its collaborator, Moffit Cancer Center, has received FDA approval for an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.
  • What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology.
  • 交易:Anixa生物科技公司(納斯達克:ANIX)董事Arnold m Baskies以平均價格3.09美元購買了5000股。爲了獲得這些股票,花費約爲15450美元。
  • 正在發生的事情:7月23日,Anixa生物科技宣佈其合作伙伴莫法特癌症中心獲得了FDA批准,針對可能對初始治療展示臨床活性的患者進行個體化的新藥申請(IND),以允許進行第二次CAR-t療法治療。
  • Anixa生物科技公司是一家專注於癌症的生物技術公司,正在開發針對腫瘤學中關鍵未滿足需求的疫苗和治療方法。

Lifeloc Technologies

Lifeloc Technologies

  • The Trade: Lifeloc Technologies, Inc. (OTC:LCTC) CFO Vern D Kornelsen acquired a total of 45,620 shares at an average price of $3.80. The insider spent around $173,356 to buy those shares.
  • What's Happening: On July 26, Lifeloc Technologies named Adam Kashenberg to its Board of Directors.
  • What Lifeloc Technologies Does: Lifeloc Technologies Inc is a developer, manufacturer, and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education.
  • 交易:Lifeloc Technologies公司(場外交易:LCTC)首席財務官Vern D Kornelsen以平均價格3.80美元購買了45620股。內部人士花費約173356美元購買這些股票。
  • 正在發生的事情:7月26日,Lifeloc Technologies任命Adam Kashenberg爲其董事會成員。
  • Lifeloc Technologies公司是便攜式掌持式及固定位呼氣式酒精測試儀及相關附件、用品和教育的開發、製造和銷售商。

Cyanotech

賽安諾科技

  • The Trade: Cyanotech Corporation (OTC:CYAN) Director Michael A / Davis acquired a total of 10,000 shares at an average price of $0.62. The insider spent around $6,200 to buy those shares.
  • What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.
  • What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.
  • 交易:Cyanotech公司(場外交易:CYAN)董事Michael A/Davis以平均價格0.62美元購買了10000股。內部人士花費約6200美元購買這些股票。
  • 近況:6月26日,Cyanotech報告稱,2024財年淨銷售額爲2,307.1萬美元,而2023財年爲2,317.8萬美元。
  • 賽安諾科技公司從微藻中提煉可用於營養補充劑市場的天然產品。
  • Top 3 Risk Off Stocks That Are Set To Fly In July
  • 7月份即將飛漲的前3只風險股票
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論